AN2 Therapeutics (ANTX) CDO Chanda Sanjay Receives RSU Awards

What Happened Chanda Sanjay, Chief Development Officer of AN2 Therapeutics (ANTX), received equity awards on February 20, 2026: 38,000 restricted stock units (RSUs) (grant reported as A) and 77,000 RSU-style derivative units (reported as A/derivative). Both awards are reported at $0.00 per share (typical for compensation awards), totaling 115,000 shares granted. These are awards/compensation grants rather than open-market purchases or sales.

Key Details

• Transaction date: February 20, 2026; Form 4 filed February 23, 2026 (appears timely).
• Price: $0.00 per share for both grants (award/compensation).
• Total shares granted: 38,000 (A) + 77,000 (A, derivative) = 115,000.
• Shares owned after transaction: not specified in the excerpt provided; the filing notes an adjusted total that includes a prior ESPP purchase (see F3).
• Footnotes of note:
  • F1: The 38,000 RSUs vest 1/4 annually over four years starting January 1, 2026, subject to continued service.
  • F2: The 77,000 derivative award "includes a balance" described as (a) 27,500 RSUs vesting 1/4 annually from Jan 1, 2024 and (b) 50,250 RSUs vesting 1/4 annually from Jan 1, 2025, each subject to continued service.
  • F3: The filing’s adjusted total reflects a purchase of 5,000 shares under the issuer’s 2022 ESPP on March 31, 2025.
  • F4: Separate option holdings (if any) vest 1/48th monthly over four years from Jan 1, 2026, subject to continued service.
• No sale or open-market purchase; this is a compensation grant (generally considered routine).

Context RSU awards reported at $0 indicate compensation-based grants that vest over time and require the executive’s continued service to the company; they are not immediate cash or market trades. Derivative-designated entries here refer to RSUs/other equity-based awards with specific vesting schedules (see F1–F2). For retail investors, such grants are common for executive compensation and do not by themselves indicate a buy or sell signal.